kabutan

Kyowa Kirin Co., Ltd.(4151) Summary

4151
TSE Prime
Kyowa Kirin Co., Ltd.
2,361.0
JPY
-44.0
(-1.83%)
Apr 30, 1:00 pm JST
14.71
USD
Apr 30, 12:00 am EDT
Result
PTS
outside of trading hours
2,356.6
Apr 30, 12:46 pm JST
Summary Chart Historical News Financial Result
PER
16.4
PBR
1.38
Yield
2.96%
Margin Trading Ratio
33.62
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
2,411.5 JPY 15.05 USD
Previous Close Apr 28
2,405.0 JPY 15.10 USD
High Apr 30, 9:00 am
2,420.0 JPY 15.10 USD
Low Apr 30, 9:16 am
2,322.0 JPY 14.50 USD
Volume
554,700
Trading Value
1.31B JPY 8.15M USD
VWAP
2356.52 JPY 14.69 USD
Minimum Trading Value
236,100 JPY 1,471 USD
Market Cap
1.24T JPY 7.76B USD
Number of Trades
2,424
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
High
1-Year Average
3,154
1-Year High Mar 5, 2026
12,784
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 66,700 99,400 1.49
Apr 17, 2026 65,100 88,500 1.36
Apr 10, 2026 68,000 82,700 1.22
Apr 3, 2026 63,900 101,100 1.58
Mar 27, 2026 52,500 152,300 2.90
Company Profile
Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Group, focusing on pharmaceutical business and new drug development through its biotechnology division. The company has formed a partnership with Fujifilm.
Sector
Pharmaceuticals
Kyowa Kirin Co., Ltd. primarily engages in the manufacture and sale of prescription pharmaceuticals. The company has numerous subsidiaries and equity-method affiliates, with Kirin Holdings as its parent company. Kyowa Kirin operates globally, with a particular focus on four key markets: Japan, North America, Europe, and Asia-Oceania. The company excels in biopharmaceutical development, possessing a unique drug discovery platform centered on antibody drug development and manufacturing technologies. Kyowa Kirin concentrates on creating new drugs that address unmet medical needs, particularly in disease areas such as nephrology, oncology, and immunology-allergy.